PolyNovo Limited

ASX:PNV Stock Report

Market Cap: AU$825.6m

PolyNovo Past Earnings Performance

Past criteria checks 4/6

PolyNovo has been growing earnings at an average annual rate of 62.2%, while the Medical Equipment industry saw earnings growing at 20.4% annually. Revenues have been growing at an average rate of 35.8% per year. PolyNovo's return on equity is 15.9%, and it has net margins of 10.3%.

Key information

62.20%

Earnings growth rate

62.00%

EPS growth rate

Medical Equipment Industry Growth5.82%
Revenue growth rate35.84%
Return on equity15.87%
Net Margin10.27%
Last Earnings Update30 Jun 2025

Recent past performance updates

PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 03
PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Recent updates

At AU$1.38, Is PolyNovo Limited (ASX:PNV) Worth Looking At Closely?

Sep 28
At AU$1.38, Is PolyNovo Limited (ASX:PNV) Worth Looking At Closely?

PolyNovo Limited (ASX:PNV) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Sep 11
PolyNovo Limited (ASX:PNV) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Returns Are Gaining Momentum At PolyNovo (ASX:PNV)

Jul 18
Returns Are Gaining Momentum At PolyNovo (ASX:PNV)

An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 38% Undervalued

Jun 13
An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 38% Undervalued

PolyNovo Limited's (ASX:PNV) 25% Jump Shows Its Popularity With Investors

May 22
PolyNovo Limited's (ASX:PNV) 25% Jump Shows Its Popularity With Investors

Is There Now An Opportunity In PolyNovo Limited (ASX:PNV)?

May 08
Is There Now An Opportunity In PolyNovo Limited (ASX:PNV)?
User avatar

NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects

Launch of NovoSorb MTX in the U.S. and geographic expansion could drive revenue growth and diversify revenue sources.

PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 03
PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

PolyNovo Limited's (ASX:PNV) Share Price Is Still Matching Investor Opinion Despite 37% Slump

Feb 26
PolyNovo Limited's (ASX:PNV) Share Price Is Still Matching Investor Opinion Despite 37% Slump

An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 39% Undervalued

Feb 11
An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 39% Undervalued

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Oct 10
Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Aug 28
PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Aug 06
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

May 08
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

When Should You Buy PolyNovo Limited (ASX:PNV)?

Feb 28
When Should You Buy PolyNovo Limited (ASX:PNV)?

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Feb 02
Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08
PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22
Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26
When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30
Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18
Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23
Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05
Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16
Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01
PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29
What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Revenue & Expenses Breakdown

How PolyNovo makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:PNV Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 25129131040
31 Mar 2512210970
31 Dec 241166880
30 Sep 241096850
30 Jun 241035830
31 Mar 24933750
31 Dec 23832670
30 Sep 2375-2610
30 Jun 2366-5550
31 Mar 2359-6510
31 Dec 2253-7470
30 Sep 2248-4390
30 Jun 2242-1320
31 Mar 22380290
31 Dec 21351260
30 Sep 2132-2270
30 Jun 2129-5270
31 Mar 2127-5260
31 Dec 2025-5250
30 Sep 2024-5230
30 Jun 2022-4210
31 Mar 2020-4190
31 Dec 1918-4170
30 Sep 1916-3150
30 Jun 1914-3120
31 Mar 1912-4110
31 Dec 189-590
30 Sep 188-590
30 Jun 187-680
31 Mar 186-680
31 Dec 175-680
30 Sep 174-680
30 Jun 174-570
31 Mar 174-460
31 Dec 165-350
30 Sep 164-350
30 Jun 163-350
31 Mar 162-340
31 Dec 150-240
30 Sep 150-230
30 Jun 150-130
31 Mar 150-230
31 Dec 140-330

Quality Earnings: PNV has a high level of non-cash earnings.

Growing Profit Margin: PNV's current net profit margins (10.3%) are higher than last year (5.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PNV has become profitable over the past 5 years, growing earnings by 62.2% per year.

Accelerating Growth: PNV's earnings growth over the past year (151.2%) exceeds its 5-year average (62.2% per year).

Earnings vs Industry: PNV earnings growth over the past year (151.2%) exceeded the Medical Equipment industry 24.7%.


Return on Equity

High ROE: PNV's Return on Equity (15.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/09 03:38
End of Day Share Price 2025/12/09 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PolyNovo Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Lyanne HarrisonBofA Global Research
Waradana Malitha De SilvaCLSA